Do analysts rate THAR or CEPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cantor Equity Partners 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, THAR or CEPO?

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Cantor Equity Partners N/A N/A -$6.66M -$0.29 N/A

Is THAR or CEPO more profitable?

Cantor Equity Partners' return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Cantor Equity Partners N/A N/A -0.74%

Do analysts rate THAR or TROO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TROOPS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, THAR or TROO?

Tharimmune has higher earnings, but lower revenue than TROOPS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A TROOPS $17.10M 15.43 -$27.91M N/A N/A

Is THAR or TROO more profitable?

TROOPS's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% TROOPS N/A N/A N/A

Do analysts rate MAAS or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maase 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, MAAS or THAR?

Tharimmune has lower revenue, but higher earnings than Maase. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maase $109.05M 2.43 -$27.36M N/A N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is MAAS or THAR more profitable?

Maase's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Maase N/A N/A N/A Tharimmune N/A -588.45% -264.41%

Do analysts rate TONX or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verb Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer THAR or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, THAR or CNTN?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A

Is THAR or CNTN more profitable?

Hillstream Biopharma's return on equity of -20.06% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Hillstream Biopharma N/A -20.06% -15.90%

Tharimmune (THAR) Competitors

$2.08 -0.20 (-8.77%)

As of 09/2/2026

Compare

THAR vs. CEPO, TROO, MAAS, TONX, and CNTN

Should you buy Tharimmune stock or one of its competitors? Tharimmune's main competitors and comparable companies include Cantor Equity Partners (CEPO), TROOPS (TROO), Maase (MAAS), Verb Technology (TONX), and Hillstream Biopharma (CNTN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Tharimmune compare to Cantor Equity Partners?

Tharimmune (NASDAQ:THAR) and Cantor Equity Partners (NASDAQ:CEPO) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Cantor Equity Partners' return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Cantor Equity Partners	N/A	N/A	-0.74%

1.2% of Tharimmune shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Cantor Equity Partners	N/A	N/A	-$6.66M	-$0.29	N/A

In the previous week, Cantor Equity Partners had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Cantor Equity Partners and 0 mentions for Tharimmune. Cantor Equity Partners' average media sentiment score of 1.95 beat Tharimmune's score of 0.00 indicating that Cantor Equity Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Cantor Equity Partners	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cantor Equity Partners	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Cantor Equity Partners has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

Summary

Cantor Equity Partners beats Tharimmune on 6 of the 10 factors compared between the two stocks.

How does Tharimmune compare to TROOPS?

Tharimmune (NASDAQ:THAR) and TROOPS (NASDAQ:TROO) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

TROOPS's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
TROOPS	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TROOPS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Tharimmune shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Comparatively, 1.1% of TROOPS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tharimmune has higher earnings, but lower revenue than TROOPS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
TROOPS	$17.10M	15.43	-$27.91M	N/A	N/A

In the previous week, TROOPS had 14 more articles in the media than Tharimmune. MarketBeat recorded 14 mentions for TROOPS and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.00 beat TROOPS's score of -0.56 indicating that Tharimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Tharimmune	Neutral
TROOPS	Negative

Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, TROOPS has a beta of 3.55, suggesting that its share price is 255% more volatile than the broader market.

Summary

TROOPS beats Tharimmune on 5 of the 9 factors compared between the two stocks.

How does Tharimmune compare to Maase?

Maase (NASDAQ:MAAS) and Tharimmune (NASDAQ:THAR) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

1.2% of Tharimmune shares are owned by institutional investors. 87.6% of Maase shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Maase's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maase	N/A	N/A	N/A
Tharimmune	N/A	-588.45%	-264.41%

In the previous week, Maase had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Maase and 0 mentions for Tharimmune. Maase's average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score.

Company	Overall Sentiment
Maase	Neutral
Tharimmune	Neutral

Tharimmune has lower revenue, but higher earnings than Maase.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maase	$109.05M	2.43	-$27.36M	N/A	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maase	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Maase has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Summary

Maase beats Tharimmune on 5 of the 8 factors compared between the two stocks.

How does Tharimmune compare to Verb Technology?

Verb Technology (NASDAQ:TONX) and Tharimmune (NASDAQ:THAR) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Tharimmune has a net margin of 0.00% compared to Verb Technology's net margin of -497.15%. Verb Technology's return on equity of -60.82% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verb Technology	-497.15%	-60.82%	-59.56%
Tharimmune	N/A	-588.45%	-264.41%

In the previous week, Verb Technology had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Verb Technology and 0 mentions for Tharimmune. Verb Technology's average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score.

Company	Overall Sentiment
Verb Technology	Neutral
Tharimmune	Neutral

Tharimmune has lower revenue, but higher earnings than Verb Technology. Verb Technology is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verb Technology	$12.78M	14.74	-$148.48M	-$1.04	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Verb Technology has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

7.2% of Verb Technology shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 21.4% of Verb Technology shares are held by insiders. Comparatively, 6.7% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verb Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Verb Technology beats Tharimmune on 7 of the 11 factors compared between the two stocks.

How does Tharimmune compare to Hillstream Biopharma?

Tharimmune (NASDAQ:THAR) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hillstream Biopharma's return on equity of -20.06% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Hillstream Biopharma	N/A	-20.06%	-15.90%

In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Hillstream Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Tharimmune	Neutral
Hillstream Biopharma	Neutral

Summary

Hillstream Biopharma beats Tharimmune on 5 of the 8 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

THAR vs. The Competition

Export

Metric	Tharimmune	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$78.48M	$27.28B	$14.12B	$12.73B
Dividend Yield	N/A	6.06%	5.89%	8.86%
P/E Ratio	-0.52	19.84	26.10	25.38
Price / Sales	N/A	453.86	533.14	92.60
Price / Cash	N/A	152.05	38.37	52.26
Price / Book	3.06	3.18	2.13	6.14
Net Income	-$12.20M	$1.10B	$1.32B	$349.01M
7 Day Performance	-6.73%	0.14%	0.13%	-1.47%
1 Month Performance	7.77%	12.87%	1.95%	2.47%
1 Year Performance	-56.39%	0.63%	12.28%	15.84%

Tharimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
THAR Tharimmune	N/A	$2.08 -8.8%	N/A	-56.2%	$78.48M	N/A	N/A	2
CEPO Cantor Equity Partners	0.6627 of 5 stars	$10.76 flat	N/A	+3.4%	$274.38M	N/A	N/A	2	Short Interest Increase High Trading Volume
TROO TROOPS	0.3211 of 5 stars	$2.20 +11.1%	N/A	+105.8%	$268.75M	$17.10M	N/A	20
MAAS Maase	0.4496 of 5 stars	$16.54 +11.8%	N/A	+402.9%	$263.32M	$109.05M	N/A	550
TONX Verb Technology	0.9413 of 5 stars	$3.42 +14.8%	N/A	N/A	$188.35M	$30.80M	N/A	170	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:THAR) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tharimmune (THAR) Competitors

THAR vs. CEPO, TROO, MAAS, TONX, and CNTN

How does Tharimmune compare to Cantor Equity Partners?

Summary

How does Tharimmune compare to TROOPS?

Summary

How does Tharimmune compare to Maase?

Summary

How does Tharimmune compare to Verb Technology?

Summary

How does Tharimmune compare to Hillstream Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tharimmune (THAR) Competitors

THAR vs. CEPO, TROO, MAAS, TONX, and CNTN

How does Tharimmune compare to Cantor Equity Partners?

Is THAR or CEPO more profitable?

Do institutionals and insiders believe in THAR or CEPO?

Which has stronger valuation & earnings, THAR or CEPO?

Does the media prefer THAR or CEPO?

Do analysts rate THAR or CEPO?

Which has more risk & volatility, THAR or CEPO?

Summary

How does Tharimmune compare to TROOPS?

Is THAR or TROO more profitable?

Do analysts rate THAR or TROO?

Do institutionals & insiders have more ownership in THAR or TROO?

Which has higher valuation & earnings, THAR or TROO?

Does the media prefer THAR or TROO?

Which has more volatility and risk, THAR or TROO?

Summary

How does Tharimmune compare to Maase?

Do institutionals and insiders have more ownership in MAAS or THAR?

Is MAAS or THAR more profitable?

Does the media prefer MAAS or THAR?

Which has preferable earnings and valuation, MAAS or THAR?

Do analysts rate MAAS or THAR?

Which has more risk & volatility, MAAS or THAR?

Summary

How does Tharimmune compare to Verb Technology?

Is TONX or THAR more profitable?

Does the media favor TONX or THAR?

Which has better earnings and valuation, TONX or THAR?

Which has more risk and volatility, TONX or THAR?

Do institutionals & insiders believe in TONX or THAR?

Do analysts rate TONX or THAR?

Summary

How does Tharimmune compare to Hillstream Biopharma?

Which has preferable valuation & earnings, THAR or CNTN?

Which has more volatility & risk, THAR or CNTN?

Do analysts prefer THAR or CNTN?

Do institutionals and insiders believe in THAR or CNTN?

Is THAR or CNTN more profitable?

Does the media refer more to THAR or CNTN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools